VOLUME - 10, ISSUE - 03, MARCH - 2021 • PRINT ISSN No. 2277 - 8160 • DOI : 10.36106/gjra

Original Research Paper

Paediatrics

PREVALENCE OF HIV IN MULTIPLE TRANSFUSED THALASSEMIA PATIENTS

Dr. Mani Kant	Senior Resident, Dept. of Paediatrics, AIIMS, Patna.
Dr. Sweta*	Senior Resident, Dept. of Dentistry, GDMC, Durgapur.*Corresponding Author
Dr. Syama Prasad Sit	Associate Professor, Dept. of Paediatrics, BSMC&H, Bankura.
Prof. Snehansu Chakraborti	Professor and HOD, Dept. of Paediatrics, BSMC&H, Bankura.

ABSTRACT

Background: Thalassemia is the most common monogenic disorder in the world. Main stay of treatment in β Thalassemia major is frequent blood transfusion and chelation therapy. Due to multiple blood transfusions; Transfusion Transmitted Infection (TTI) is a major challenge to the transfusion services all over the world. This study was aimed to estimate the prevalence of HIV in multiple blood transfused patients of β thalassaemia major. **Materials and Methods:** Prospective cross sectional study was conducted at BSMC&H, West Bengal between june 2015 to May 2016 among βThalassemia major patients up to 12 years of age received >5 blood transfusions. Total 200 samples were taken who fulfilled the inclusion criteria made for our study. Seropositivity status data were collected and analysed using Microsoft excel data sheet and IBM SPSver.22. P-value <0.005 was considered significant.**Results:** Out of total 200 thalassemia children enrolled in the study,18 were tested positive for HIV.Seropositivity status is multifactorial which was analysed in our study. **Conclusion:** My study done on transfusion dependent β-thalassemia major children showed significant number of cases were reactive for HIV. It was also seen that no. of transfusions is directly proportional to the prevalence of seropositivity . Education level of parents & other socio-economic factors has also some bearing in prevalence of seropositivity bcz patient may acquire infections from sources other than blood or blood products like reused needle & syringes, surgical operations, dental procedures, ear nose procedures etc.

KEYWORDS : β Thalassemia,HIV

I.INTRODUCTION

Thalassemia is the most common monogenic disorder in the world. It had been traditionally prevalent in and confined to the Mediterranean basin, Middle East, North India, Southeast Asia and the Indochina Peninsula. However, immigration of those populations to USA, Canada, and Western European countries has resulted in a more universal distribution of the disease.[1] Therefore, it should currently be considered a global rather than a regional health problem. In India approximately 3-10% of people carry thalassemic gene.[2]

The combination of blood transfusion and chelation therapy has dramatically prolonged the life expectancy of these patients, thus transforming thalassaemia from a rapidly fatal disease of childhood to a chronic disease compatible with a prolonged life.[3] On the other hand, frequent blood transfusions leading to iron overload and the chronic nature of the disease have contributed to a whole new spectrum of complications in adolescents and young adults suffering from thalassemia major.[2]Transfusion Transmitted Infection (TTI) is a major challenge to the transfusion services all over the world. The problem of TTI is directly proportional to the prevalence of the infection in the blood donor community. Our study was limited to multiple blood transfused thalassaemia major patients. This study was aimed to estimate the prevalence of HIV in multiple blood transfused patients of thalassaemia major.

II. AIMS & OBJECTIVES

In developing countries, use of reused needles and syringes for therapeutic injections and improper sterilization of invasive medical devices is the major vehicle for transmission of blood borne organisms including *HIV1&2*. Hence the purpose of this study was to evaluate the seropositivity of *HIV* among Thalassemia patients transmitted by blood transfusion.

SPECIFIC OBJECTIVES OF THE STUDY:

The specific objectives of this study were:

1. To estimate the prevalence of HIV amongst multiple blood transfused patients of β thalassaemia major.
2. To evaluate information regarding blood transfusion dependent β thalassemic patients in relation to age, sex, blood group, total number of transfusion.
3. To determine association of TTIs in relation to number of transfusions.

III. MATERIALS AND METHODS

STUDY AREA:

Department of pediatric medicine , BSMC&H.

STUDY POPULATION:

Diagnosed cases of thalassemic children upto 12 years of age admitted in indoor of the Department of Paediatric Medicine of Bankura Sammilani Medical college and Hospital, West Bengal.

STUDY PERIOD: One year (1st June 2015 to 31 May 2016)

SAMPLE SIZE: From the previous 3 years record of average number of children admitted with thalassemia to indoor of Pediatric medicine Dept., the expected available patients during my study period was around 200. Therefore, we proposed to study a population of at least 200 consecutive children with thalassemia.

SAMPLE DESIGN: Sample were selected from thalassemic children if they fulfil the inclusion criteria (as mentioned below) and parents voluntarily giving consent to participate in study.

INCLUSION CRITERIA:

a. All diagnosed patients of thalassemia admitted in thalassemia unit of our institution.

b. Age Group—up to 12 completed years irrespective of their age, sex &religion
c. Thalassemic patients whose parents gave consent to take part in thestudy.
d. Patients who had received at least 5 tarnsfusions in the past

EXCLUSION CRITERIA:
a. Patients more than 12 years of age
b. Thalassemic patients whose parents had not given consent to takepart in the study.
c. patients received <5 tansfusions
d. patients who had transfusions from private institutes

STUDY DESIGN: Prospective cross sectional study

PARAMETERS TO BE STUDIED:
For objective no.1:
Anti HIV 1 &2 Ab status of the patient

For objective no.2:
Age of the patient
Sex of the patient
Blood group of the patient
No. of transfusions received by the patient

For objective no.3:
To determine whether prevalence of infection is related to the no. of transfusions

STUDY TOOLS:
1. Predesigned proforma
2. HPLC report
3. Anti HIV 1 & 2 Ab reports (by immunoassay) to be done in ICTC Centre in BSMCH
4. Clinical assessment of the patients
[kit used for anti-HIV was Bio test kit from Germany].

Study Technique:
After obtaining ethical clearance from the Institutional Ethics Committee, study was conducted among the study population after taking written informed consent from the guardian /parents. Keeping compliance with Helsinki Declaration, 1964 for Medical Research involving Human Subjects, the parents of the selected patients were informed verbally about the study design, the purpose of the study and their right to withdraw their children from the study at any time, for any reason .The entire diagnosed thalassemia patient admitted in thalassemia unit was thoroughly examined and enquired for any blood trasnsfusion transmitted infection by reviewing their previous documents and test reports available with them because in our set up we used to do testing of serological status of all patients 6 monthly .

Plan for analysis of data:
Data were collected, recorded & compiled on Microsoft Excel data sheet.Statistical methods (mean, standard deviation) and IBM SPSS ver. 22 was used to analyse the data. Study of significance was analysed by Chi square test for qualitative data and Student t-test for quantitative data. P value <0.05 was considered significant.

IV. RESULTS
Out of total 200 thalassemia children enrolled in the study, 112 (56% n=200) were boys and 88 (44% n=200) were girls. 159 (79.5% n=200) were non- tribals and 41 (20.5% n=200) were tribals. Out of total 200 patients 6(3%) were below 2 yrs of age, in 2to 5 year age group there were 50(25%) patients. 80(40%) & 64(32%) patients were respectively in 6 to 9 & 10 to 12 year age group. Mean age of patients was 7.5 ± 2.94. The youngest patients in the study was 1 year 5 months old & eldest patient 12 years old. Thalassemic children in the study population received first blood transfusion at mean age of 10.75 ± 5.31 months.Their maximum age for first transfusion was 27 months and minimum age, 3 months. In my study mean no. of transfusions received by study population was 55.89±33.53. Maximim no. of transfusions received by a patient was 145, 2 patients one of 11yrs. old & other of 12 yrs old received 145 transfusions ; minimum no. of transfusions i.e. 5 was received by 2 patients one of 1yr 11month old & other one was 2 yrs old female baby.

Table-1: Seropositivity status in relation to number of transfusion

Number of Transfusions	HIV+
5-25	1
26-50	7
51-75	2
76-100	3
101-125	4
126-150	1
Total	18

Maximum no. of seropositive patients were those who received total no. of transfusions between 26-50; 7 were HIV reactive. In the group which received >125 transfusions;one patrient was HIV reactive. Minimum no. of seropositive patients in the group which received transfusions in between 5 to 25,one patient was seropositive.

Table-17: Comparison of factors between HIV + & HIV- patients

Factors		HIV positive	HIV negative	p-value
AGE	<2	0	6	0.123
	2-5	2	48	
	6-9	6	74	
	10-12	10	54	
AOFT	0-6	7	37	0.441
	7-12	6	87	
	13-18	4	45	
	19-24	1	9	
	>25	0	4	
NOT	5-25	1	45	0.049
	26-50	7	46	
	51-75	2	46	
	76-100	3	28	
	101-125	4	11	
	126-150	1	6	
Edu. F	I	5	9	<0.01
	P	5	7	
	M	2	51	
	S	6	115	
Edu. M	I	13	56	0.005
	P	2	26	
	M	1	35	
	S	2	65	

AOFT-Age of first transfusion
NOT- Number of transfusions

V. DISCUSSION

Table no.-3:Seropositivity Status(Indian studies)

Sr.no.	Author	Place	Publication year	Sample size	HIV Positivity	HBsAg Positivity	HCV Positivity
1.	ChakrabartiS et al[4]	Kolkata, India	2006	20	0%	5%	5%

2.	Bhavsaret Al[5]	Ahmedabad, India	2009	100	9%	6%	18%
3.	Twisha Oza et Al[6]	Gujarat, India	2011	193	3.1%	0.52%	7.8%
4.	SoniP et al[7]	Ahmedabad, India	2012	136	0%	1.47%	20.58%
5.	NeerjaH Shah et al[8]	Gujarat, India	2016	55	3.63%	0%	36.36%
6.	Biswas Aritra et al[9]	Kolkata, India	2014	1711	3.74%	3.33%	18.70%
7.	Present Study	Bankura, India	----	200	9%	--	--

Table no.-4:Seropositivity Status(Foreign studies)

Sr. no.	Author	Place	Publication year	Sample size	HIV Positivity	HBsAg Positivity	HCV Positivity
1.	AKM Rezaul Karim et al[10]	Bangladesh	2013	100	0%	3%	31%
2.	Al-Sheyyab et al[11]	Jordan	2001	143	0%	3.5%	40.5%
3	Mirmomn et al[12]	Iran	2006	732	0%	1.5%	19.3%

In my study out of 200 patients, 18 i.e. 9% were tested positive for HIV which was a similar finding with the study done by Bhavsar et al[5] in Gujrat. Twisha oza et al[6], Neerja shah et al[8]& Aritra Biswas et al[9] studies had also shown the seropositivity for HIV is 3-4% which was too less than that of my study. Foreign studies had shown ZERO seropositivity for HIV in their patients.

Number of transfusions

In my study those patients who received transfusions less than 50 in no. 4% were positive for HIV. In 50 to 100 transfusions received patients 1.5%were HIV positive . In those who received transfusions between 101 to 150; 2.5% HIV reactive. In the study conducted by Hardik Bhavsar et al[5] in first group i.e. between 0-50; 3% were HIVreactive, in second group(51-100), seropositivity was 3%for HIV. In last group(101-150),there were no seropositive patients. In my study no patient had received transfusions more than 150 ,since the maximum age limit of study population was 12 with respect to 17 in their study. In the aforesaid study the mean of no. of transfusions was 66.44±53.72 but in my study mean was 55.89±33.53 since age limit in my study was 12 years in comparison to 17 years in their study.P- value for HIV is <0.05. Hence ," **with increasing no. of transfusions seropositivity increases"** this statement is statistically significant in case of my study.

VI. SUMMARY

Transfusion transmitted infection is the major determinant of prognosis and survival in β -thalassemia. In my study total 200 β-thalassemia major patient came for blood transfusion in pediatric emergency ,were examined clinically & relevant data were taken w.r.t. Seropositivity for HIV.Their pre transfusion hemoglobin levels ,serum ferritin levels detected and enquiry was done about their socio-economic status.

Out of 200 patients enrolled in the study 56%were boys& 44% were girls. 79.5% patients belong to non-tribal community & 20.5% were from tribal community. Maximum patients in my study wa in 6-9 year age group(40%) ; 2nd largest age group was 10-12 years. Only 6 patients were of below 2 year age.

Those patients who received their first transfusion below 1 year of age had shown maximum seropositivity. In the group who received their first transfusion below 6 months of age; 7 were positive for HIV; receiving transfusion between 7-12 months of age make 6 patients HIV reactive . Those patients whose age of first transfusion was between 19-24 months of age single patient tested positive for HIV & no seropositive patient in the group who received their first transfusion after 24 months of age. Receiving first transfusion at very early age implied that patient will need more transfusions in future & hence more chance of acquiring infections.

VII. CONCLUSION

In conclusion, my study done on transfusion dependent - thalassemia major children shows significant number of cases are reactive for Anti HIV I& II Ab . It is also seen that no. of transfusions is directly proportional to the prevalence of seropositivity. Education level of parents & other socio-economic factors has also some bearing in prevalence of seropositivity bcz patient may acquire infections from sources other than blood or blood products like reused needle & syringes, surgical operations, dental procedures, ear nose procedures etc.

HIV,HCV and HBV are still prevalent in multi-transfused β-thalassemia patients. Strict donor selection, education of patients about benefit of HBV vaccine and standard serological techniques for screening of blood product such as nucleic acid amplification test (NAAT) and PCR by blood bank might reduce the prevalence of TTI. At present, the majority of blood banks including ours in this country are not using NAAT due to the cost, which is 5–6 times as compared to ELISA. We think it is a nationwide issue and needs urgent attention. The government should take measures to cut down the cost of NAAT and make it mandatory for all blood banksin this country so that a patient requiring chronic transfusion will have minimum risk of TTI.

Lastly, I must admit that this study done in a limited number of study population. The study period is also only one year. So a larger study done on a longer period will be able to define the situation more accurately.

REFERENCES

1. Kremastinos DT, Tsiapras DP, Kostopoulou AG, Hamodraka ES, Chaidaroglou AS, Kapsali ED. NT-proBNP levels and diastolic dysfunction inbeta-thalassaemia major patients. Eur J Heart Fail. 2007;9:531–536.
2. Jain M, Sinha RSK, Ghellani H, Anand NK. Asssessment of thyroid functions and its role in body growth in thalassemia major. Indian Pediatr February 1995;.32: 213-219.
3. Ehlers KH, Levin AR, Markenson AL, Marcus JR, Klein AA, Hilgartner MW, et al. Longitudinal study of cardiac function in thalassemia major. Ann N Y AcadSci 1980;344:397-404.
4. Chakrabarti S. Pradhan P. Roy A et al - Prevalence of anti HCV, HBsAg and HIV Ab in high risk recipients of blood products dept of pathology NRS. Med. College Kolkata - IJ. Public health 2006. Jan - Mar. 50(1) P. 43 - 44.
5. HardikBhavsar, Kanu Patel, MahendraVegad,Molly Madan, Anita Pandey, AshishAsthana, KalpeshMistry. Prevalence of HIV, Hepatitis B and Hepatitis C infection in Thalassemiamajor patients in tertiary care hospital, Gujarat, NJIRM 2011; Vol. 2(3). July- September.
6. Dr.TwishaOza ,Dr.AmitAgrawat ,Dr.GauraviDhruva , Dr. H.V. Oza, A Study Of Prevalence Of HIV, HbsAg And HCV In Thalassemia Major Children, NJIRM 2012 ; Vol. 3(4). September- October
7. Dr. Payal Soni, Dr. Nisarg Trivedi, Dr. Parevee Shah, Dr. Dipa Kinariwala, Dr. Sumeeta Soni, Dr. P. K. Shah A Prevalence Of HIV, HBV and HCV In Patients of Thalassemia International Journal of Scientific Research, Vol : 3, Issue : 9 September 2014
8. Shah NH, Shrivastav A, Bhavsar U, Agnihotri AS. Study of prevalence of seropositivity in multi-transfused thalassemia patients – A hospital based study. Int J Med Sci Public Health, [cited September 25, 2016]; Online First: 25 May, 2016.

9. Biswas A et al- Prevalence of Anti-HCV,HBsAg, HIV among multi-transfused thalassemic individuals and their socio-economic background in eastern India; Asian J Pharm Clin Res, Vol 9, Issue 1, 2016, 314-318
10. AKM REZAUL KARIM et al- Seroprevalence of Hepatitis B, Hepatitis C and HumanImmunodeficiency Virus Among Multitransfused Thalassaemic Children in Dhaka, Bangladesh; BANGLADESH J CHILD HEALTH 2013; VOL 37 (3) : 146-153
11. Al Sheyyab, M., Batieha, A. & Al Khateeb, M. (2001) The prevalence of HBV, HCV, and HIV markers in multi transfused patients. Journal of Tropical Pediatrics, 47, 239–242.
12. Mirmomen, S., Alavian, S.M., Hajarizadeh, B. et al. (2006) Epidemiology of HBV, HCV and HIV in patients with beta thalassemia in Iran: a multicenter study. Archives of Iranian Medicine, 9, 319–323.